GEIS: When a Complex Case Is Managed by More Than One Medical Center

Recently, during a conversation with Dr. Antonio López Pousa, one name came up again and again: GEIS. And I would like to explain to parents why these four letters truly represent hope.

GEIS is the Spanish Group for Research on Sarcomas. Dr. López Pousa was one of its founders. The group was established in 1994, when doctors recognized that sarcomas are too rare and too diverse for any single specialist or hospital to know everything about them.

Today, GEIS brings together doctors from more than 60 medical centers across Spain. They include oncologists, surgeons, pediatric specialists, pathologists, radiation oncologists, and molecular researchers. They share expertise, develop clinical guidelines, and conduct clinical trials together.

For families, this means something very important: their case is not confined to a single medical center.

First, an expert reviews the pathology and determines the exact subtype of sarcoma. This is critically important because after a specialized review, the diagnosis may be refined or changed, and with it, the prognosis and the entire treatment plan. The doctors then look for the best possible pathway for that particular patient.

• For example, treatment may initially be provided by Dr. López Pousa’s team at his medical center. Later, the patient may need a specific operation, technology, or clinical trial available at another center in Spain. In that case, the patient is referred there while professional coordination between specialists is maintained. GEIS does not tie a patient to a single hospital. Its role is to bring together the expertise of different centers and facilitate access to new medicines and treatment approaches.

The group’s website lists ongoing clinical trials for different types of sarcoma, including locally advanced and metastatic disease. And if there is no suitable option in Spain, the specialists’ international connections make it possible to consider clinical trials in other countries, including the United States.

I want to emphasize again that I do not want this to sound like a promise of a miracle. Not every patient will meet the eligibility criteria for a clinical trial. And doctors will not be able to offer a new treatment option in every situation. But to me, this is hope.

Hope is when one doctor does not have to face a complex diagnosis alone. When they can turn to a large professional network and ask: where can we find the best option for this patient right now?

And GEIS is one example of why Spain is so strong in the treatment of rare and complex diseases. When I say that we are looking not simply for a hospital, but for the best medical pathway, this is exactly what I mean.